ClinicalTrials.gg
CompletedNCT00630110Updated Aug 16, 2011

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

A Phase 1/2 interventional study of docetaxel and NPI-2358 + docetaxel in Cancer, sponsored by Nereus Pharmaceuticals, Inc.. Completed at 36 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-16.

Sponsored by Nereus Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues.

Read the detailed description

This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues. There are indications of advantages in combining vascular disrupting agents with standard agents in the treatment of advanced non-small cell lung cancer (NSCLC).

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Non Small Cell Lung
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 172 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Nereus Pharmaceuticals, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and females ≥ 18 years of age
  • performance status ≤ 1
  • or histologically confirmed advanced non-small cell lung cancer (unresectable Stage IIIb or IV) that has progressed after treatment with at least one chemotherapy regimen; is not required for enrollment into this trial
  • All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to Grade ≤ 2
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Administration of certain chemotherapy, biological, immunotherapy, radiation therapy, surgery or agent within specified time frames
  • Significant cardiac history
  • Prior treatment with tumor vascular disruptive agents
  • Seizure disorder
  • Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy
  • Known infection with (HIV), or active hepatitis A, B, or C
  • Patients with a prior reaction to product components
  • Pregnant or breast-feeding women.
  • Concurrent, active second for which the patient is receiving therapy, excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix
  • Unwilling or unable to comply with procedures required in this protocol
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (actual)

Study arms

  • Active comparator
    docetaxel

    docetaxel (75 mg/m2)

    Drug: docetaxel

  • Experimental
    NPI-2358 + docetaxel

    NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)

    Drug: NPI-2358 + docetaxel

Interventions

  • docetaxel (75 mg/m2)

    Also known as: docetaxel (Taxotere)

  • DrugNPI-2358 + docetaxel

    Drug pages: NPI 2358 · Docetaxel

    NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)

    Also known as: NPI-2358; docetaxel (Taxotere)

06

What researchers measure

Primary outcomes

  1. Compare overall survival of patients treated with docetaxel to patients treated with docetaxel + NPI-2358

    Time frame: Continuous

Secondary outcomes

  1. Compare response rate, duration of response, 6-month survival, progression free survival and safety.

    Time frame: Continuous

  2. Pharmacokinetics

    Time frame: Continuous

07

Study locations

36 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • San Diego Pacific Oncology & Hematology Associates
    Encinitas, California 92024, United States
  • University San Diego Moores Cancer Center
    San Diego, California 92093, United States
  • Kaiser Permanente
    San Diego, California 92108, United States
  • Premiere Oncology
    Santa Monica, California 90404, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • University Texas Health Science Center at San Antonio (CTRC)
    San Antonio, Texas 78229, United States
  • Policlinica Privada Instituto de Medicina Nuclear
    Bahia Blanca, Argentina
  • Hospital Britanico
    Capital Federal, Argentina
  • Instituto Oncologico De Cordoba
    Cordoba, 5000 CRD, Argentina
  • Clinica Universitaria Privada Reina Fabiola
    Cordoba, 5000CRD, Argentina
  • Caici Centro de Asistencia e Investigacion Clinica Integral
    Rosario, Argentina
  • Hospital del Centrenario
    Rosario, Argentina
  • Mater Adult Hospital
    South Brisbane, Queensland 4101, Australia
  • Bendigo Health Care Group
    Bendigo, Victoria, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Fundacap Pip XII Hospital do Cancer de Barretos
    Barretos, Brazil
  • Hospital Erasto Gaertner Liga do Combate as Cancer
    Curitiba, Brazil
  • Associacao Hospital de Caridade Ijui
    Ijui, Brazil
  • Hospital Sao Lucas
    Porte Alegre, Brazil
  • Hospital de clinicas de Porto Alegre
    Porto Alegre, 90035, Brazil
  • Clinionco-Clinica de Oncologia de Porto Alegre
    Porto Alegre, Brazil
  • Hosp.das Clinicas da Univ.de Sao Paulo
    Sao Paulo, Brazil
  • Instituto do Cancer Aenaldo Vieira de Carvahlo
    Sao Paulo, Brazil
  • Instituto Nacional del Cancer Oncology
    Santiago, Chile
  • Hospital Carlos Van Buren
    Valparaiso, Chile
  • Chittaranjan National Cancer Institute
    Kolkata, W. Bengal 700026, India
  • Kidwai Memorial Institute of Oncology
    Bangalore, 560029, India
  • Apollo Speciality Hospital
    Chennai, 600035, India
  • Apollo Hospital
    Hyderabad, 500033, India
  • SEAROC Cancer Centre S.K. Soni Hospital
    Jaipur, 302013, India
  • Subodh Mitra Cancer Hospital & Research Centre
    Kolkata, India
  • Tata Memorial Hospital
    Mumbai, 530002, India
  • Ruby Hall Clinic
    Pune, 411011, India
  • Andhra Medical College
    Vishakhapatnam, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2008
First posted
Mar 6, 2008
Start
Feb 2008
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Last update
Aug 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00630110
Lead sponsor
Nereus Pharmaceuticals, Inc.
First posted
Mar 6, 2008
Start date
Feb 2008
Primary completion
Jun 2011
Completion
Jun 2011
Last update
Aug 16, 2011

Study contacts

Matthew A Spear, MD
study director · Chief Medical Officer, Nereus Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: NPI 2358 · Docetaxel

Start the discussion